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Introduction
Nitric oxide (NO), generated by the endothelial isoform of NO synthase (eNOS), has numerous physiological functions such as inhibition of platelet aggregation, induction of vasorelaxation, suppression of adhesion of leukocytes to the endothelium, and inhibition and migration of vascular smooth muscle cells (VSMC). Interestingly, mice lacking eNOS expression develop several pathological conditions such as hypertension, insulin resistance, hyperlipidemia (1), abnormal vascular remodeling (2) , heart failure (3), and acceleration of atherosclerosis (4) . These data suggest the im-sion in which production of vascular oxidants is upregulated (9) . Similarly, it has been reported that hypertension is associated with increased inhibition of NO signaling by superoxide, whereas NO release remains unaffected (10) . Taken together, these findings suggest that the scavenging capacity of superoxide may be critical in regulating the bioactivity of NO derived from eNOS. The enzyme superoxide dismutase (SOD) is a primary cellular defense mechanism against superoxide. Three SOD isozymes have been identified. Manganese SOD (Mn SOD) is mitochondrial and the dimeric copper/zinc-containing SOD (Cu/Zn SOD) is cytosolic and nuclear, whereas the tetrameric, proteoglycan-bound Cu/Zn SOD is extracellular (11) .
Calcium antagonists have been shown to improve endothelial function and clinical outcome in patients with hypertension (12) . Although the precise mechanisms underlying these beneficial effects are not clear, a number of possible mechanisms have previously been reported. For example, calcium antagonists normalize endothelial dysfunction through enhancement of NO function (13) , antioxidant functions (14, 15) , and inhibition of apoptosis (16) . We have recently demonstrated that calcium antagonists indirectly upregulate endothelial SOD expression by stimulating vascular endothelial growth factor (VEGF) production from adjacent vascular smooth muscle cells (VSMC) (17) . Upregulation of SOD expression by calcium antagonists results in an increase in NO production from endothelial cells (EC). Interestingly, Fukai et al. (18) recently reported that NO induces upregulation of extracellular SOD expression in VSMC. In the present study, we therefore investigated whether the calcium antagonist nifedipine modulates Mn SOD expression in VSMC via NO-dependent pathways.
Methods

Materials
Nifedipine was donated by Bayer Pharmaceutical Co. (Tokyo, Japan).
N-ethyl-2-(1-ethyl-2-hydroxy-2-nitrosohydrazino) ethanamine (NOC-12) and N G -monomethyl-L-arginine (L-NMMA) was purchased from Dojindo Laboratories (Kumamoto, Japan).
Experimental Design
A coculture experiment with EC and VSMC was performed to determine whether cellular interactions mediate the action of the calcium antagonist nifedipine in these cells. The levels of SOD activity or Mn SOD expression in VSMC cocultured with EC were compared with those in VSMC monocultures.
Cell Culture
Human umbilical vein EC were purchased from Sanko Junyaku (Tokyo, Japan) and cultured in EBM-2 (Sanko Junyaku) supplemented with 2% fetal calf serum (FCS) and antibiotics. Human VSMC were isolated from human aortas and then cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% FCS. For coculturing, EC were grown to confluence on the collagen-coated microporous membranes of transwells (Costar Corp., Cambridge, USA). VSMC cultured on 24-well plates were then cocultured with EC in EBM-2 medium containing 2% FCS. In this coculture system, these cells were separately cultured in a 1 mm distance but the culture medium was shared by both cells. Therefore, humoral interchange was allowed between them without direct cellular contact. Since nifedipine is extremely susceptible to light degradation, all nifedipine solutions were prepared and added to cell cultures under yellow light and cells were then cultured in the dark to minimize lightinduced decomposition of nifedipine.
Determination of SOD Activity
EC or VSMC were harvested following incubation for the indicated periods with treatment agents and resuspended in 100 µl of water. Cells were then lysed by freezing/thawing 3 times and centrifuged at 15,000 g for 10 min at 4 ºC. After centrifugation, the supernatants were again centrifuged at 20,000 g for 30 min. The resultant supernatant was then used for the determination of SOD activity by monitoring the inhibition of xanthine oxidase-mediated cytochrome c reduction (19) , by measuring the absorbance measured at 550 nm over 3 min.
Western Blot Analysis for Mn SOD
Harvested VSMC were treated in 10 µl/10 6 cells of lysis buffer (1% sodium dodecyl sulfate (SDS); 100 mmol/l NaCl; 50 mmol/l Tris-HCl, pH 8.0; 20 mmol/l ethylenediaminetetraacetic acid (EDTA)) and boiled for 4 min. Samples, each containing 50 µg of protein, were loaded onto a 12.5% SDS polyacrylamide gel electrophoresis (PAGE) gel, run and electroblotted onto nitrocellulose filters. Blots were blocked in 5% skimmed milk in phosphate-buffered saline (PBS) for 1 h, treated for 1 h with an antibody to Mn SOD, and then incubated with peroxidase-conjugated secondary antibodies for 1 h. Immunoblots were developed using an ECL Western blotting detection system (Amersham International Plc, Buckinghamshire, UK). The blot was then reprobed with α-tubulin to confirm equal protein loading in each well.
Cell Proliferation Assay
VSMC were preincubated for 18 h both in the presence or absence of Mn SOD antisense or sense oligodeoxyribonucleotides (ODN) (1.0 µmol/l). The Mn SOD antisense and sense ODNs used were 5 -CACGCCGCCCGACACAACAT TG-3 and 5 -CAATGTTGTGTCGGGCGGCGTG-3 , respec-tively. VSMC were then cocultured with EC in EBM-2 medium containing 2% FCS for 24 h in the pesence or absence of nifedipine. VSMC were labeled with [ 3 H]-thymidine (2 µCi/ml) during the last 4-h period of the incubation. After labeling, cells were washed three times with cold PBS and treated with 5% trichloroacetic acid and ethanol-ethylether (3:1; vol/vol). The residues in the wells were solubilized in 0.3 eq/l NaOH, and the radioactivity of aliquots of the solution was measured after neutralization of the pH.
Statistical Analysis
Within-group comparison was made by analysis of variance and Fisher's PLSD post hoc test was used to test statistical significance. Results are expressed as mean SEM. A value of p 0.05 was considered significant. Figure 1 shows the effects of cellular interactions between EC and VSMC on SOD activity in these cells during treatment with the calcium antagonist nifedipine. Interestingly, coculturing resulted in a slight increase in the levels of SOD activity in the other cells. Nifedipine had no effect on the levels of SOD activity in EC or VSMC when these cells were cultured individually. However, it induced a significant increase in the levels of SOD activity in both EC and VSMC when these cells were cocultured.
Results
Nifedipine Upregulates SOD Activity in VSMC when Cocultured with EC but Not in VSMC Monocultures
Nitric Oxide (NO) Mediates Nifedipine-Induced Upregulation of Mn SOD Expression.
To define the molecular mechanism by which nifedipine induces upregulation of SOD activity in cocultured vascular cells, we next examined the effect of nifedipine on the levels of Mn SOD expression using Western blot analysis. As 
Fig. 2. Nifedipine induces up-regulation of Mn SOD expression in VSMC cocultured with EC via NO-dependent pathways. VSMC were cocultured for 24 h with or without EC in the presence or absence of nifedipine (1 µmol/l), L-NMMA (3 mmol/l), and NOC-12 (0.5 mmol/l). A: Mn SOD expression in VSMC was determined by Western blot analysis. The blot
was then reprobed with α-tubulin to confirm equal loading of protein in each well. B: Mn SOD expression was quantified by densitometric analysis of the Western blots from 4 independent experiments (data are normalized against α-tubulin and expressed as means SEM; n 6). p 0.05, significantly different from VSMC cultured individually. p 0.05, significantly different from control VSMC cocultured with EC. p 0.05, significantly different from cocultured VSMC treated with nifedipine. p 0.05, significantly different from cocultured VSMC treated with nifedipine and L-NMMA.
shown in Fig. 2 , coculturing with EC resulted in a slight increase in the levels of Mn SOD expression in VSMC, and nifedipine induced upregulation of Mn SOD expression in VSMC cocultured with EC but not in VSMC cultured individually. These results are consistent with the results in Fig.  1 . Importantly, L-NMMA, an inhibitor of NO synthesis, partially suppressed the upregulation of Mn SOD expression induced by nifedipine. In addition, NOC-12, a NO donor, reversed this suppression by L-NMMA, suggesting that NO is involved in the mechanism underlying the upregulation of Mn SOD expression in VSMC by nifedipine.
Nifedipine Enhances Inhibition of VSMC Growth by EC through Upregulation of Mn SOD Expression
In order to define the physiological importance of the observed upregulation of Mn SOD expression in VSMC, we used Mn SOD antisense ODN to determine whether the increase in the levels of Mn SOD is related to the inhibitory effect of EC on VSMC growth. Preincubation of VSMC with Mn SOD antisense ODN abolished the nifedipine-induced upregulation of Mn SOD expression, whereas sense ODN had no effect (Fig. 3A, B ). As shown in Fig. 3C , coculturing with EC resulted in a slight inhibition of VSMC growth, and nifedipine significantly enhanced this inhibitory effect. Preincubation with Mn SOD antisense ODN significantly reversed this nifedipine-induced enhancement, whereas sense ODN had no effect. These results indicate that nifedipine-induced enhancement of the inhibitory effect of EC on VSMC growth is primarily due to upregulation of Mn SOD expression.
Discussion
In the present study we showed that cellular interactions between EC and VSMC are important in the regulation of antioxidant enzyme Mn SOD expression in VSMC. Upregulation of vascular Mn SOD expression by the calcium antagonist nifedipine is mediated through these cellular interactions. Finally, upregulation of Mn SOD expression by nifedipine results in the enhancement of VSMC growth inhibition by EC.
Hypertension is associated with increased vascular superoxide production (9) . Increased levels of vascular superoxide induce endothelial dysfunction by promoting inactivation of NO. Superoxide also induces down-regulation of contractiletype smooth muscle myosin heavy chain isoform SM2 expression in medial smooth muscle cells, which leads to an increase in aortic stiffness and reduction of vascular responsiveness in the rabbit aorta (20) . In addition, the reaction between NO and superoxide results in the formation of peroxynitrite, highly toxic metabolite that induces vascular damage. Importantly, eNOS exposure to peroxynitrite results in increased enzymatic uncoupling and generation of superoxide, further contributing to vascular injury (7, 8) . These ob- A B C servations indicate that scavenging of superoxide is very important in preventing endothelial dysfunction and vascular injury in patients with hypertension. In keeping with these observations, the present data that the calcium antagonist nifedipine upregulated Mn SOD expression in VSMC may provide some insight into the mechanism underlying the beneficial effects of calcium antagonists in patients with hypertension.
Calcium antagonists have previously been shown to normalize endothelial dysfunction in many cardiovascular diseases including hypertension (13, 21) . Although the underlying mechanism by which calcium antagonists normalize endothelial dysfunction remains to be elucidated, several possible mechanisms have been previously reported. For example, Zhang and Hintze (22) reported that calcium antagonists enhance NO production in canine coronary microvessels. Their possible antioxidant properties have been also suggested (23) . We have recently demonstrated that calcium antagonists indirectly upregulate the SOD expression in EC by stimulating VEGF production from adjacent VSMC (17) . We also demonstrated that upregulation of endothelial SOD expression by calcium antagonists resulted in an enhancement of NO production from EC. In the present study we showed that the calcium antagonist nifedipine induced upregulation of Mn SOD expression in VSMC as well. Although the precise mechanism underlying the upregulation of Mn SOD in VSMC by nifedipine is not clear at present, NO derived from adjacent EC appears to be involved in this mechanism, because L-NMMA, an inhibitor of NO synthesis, inhibited this upregulation by nifedipine. However, whether or not a similar increase in Mn SOD expression could be obtained by treatment with organic nitrates or NO donors remains to be determined. This is in agreement with the previous report by Fukai et al. (18) who showed that endothelial NO stimulates extracellular SOD expression in adjacent VSMC via cGMP-mediated pathways, thus preventing superoxide-induced degradation of NO. In the present study, we also demonstrated that upregulation of Mn SOD resulted in the enhancement of inhibitory effects of EC on VSMC growth, suggesting that upregulation of Mn SOD by nifedipine leads to the enhancement of NO bioactivity. Taken together these findings suggest that the ability of calcium antagonists to upregulate both endothelial NO production and vascular Mn SOD expression may strengthen their efficiency and physiological usefulness in patients with hypertension.
In conclusion, the results of this study demonstrate that the calcium antagonist nifedipine induces upregulation of Mn SOD expression in VSMC via cellular interactions between EC and VSMC. Thus, cellular interactions between these two cell types is considered to be involved in the molecular mechanism underlying the normalization of endothelial dysfunction by calcium antagonists.
